Kyoko Hirano

高齢かつ低心機能患者に腹膜透析(PD)を導入し、生活の質(QOL)のみならず心機能が改善した87歳男性の症例を報告した。10年前より腎硬化症による慢性腎不全にて加療中、心エコーでの所見で高度の低心機能を認めていたが、腎機能が不良のため心カテーテル検査による心精査を施行できなかった。うっ血性心不全を発症し入退院を繰り返していた。腎機能は緩徐に増悪したため、PDカテーテルを挿入し、体液量コントロールを目的にPD導入とした。導入後1年の時点で、心機能、SF-36v2によるQOL評価ともに改善を認めた。下腿の浮腫が消失し、経口摂取が改善し体重は増加した。本症例のように重度の低心機能例では、残腎機能が十分に保たれているうちからPD導入が望ましいと考えられた。本症例ではPDによって心機能が改善したが、心機能改善には血液透析(HD)にはない緩徐な除水に加え、さまざまな物質の除去が関与している可能性があり、今後HDと比較した検討が必要であることを指摘した。

Substitution therapy using levocarnitine chloride (L-carnitine 600 mg/day, 12 weeks) was carried out in 13 cases of hemodialysis patients requiring high-capacity (9,000 IU/week or more upon rHuEpo conversion) ESA, and its effect against anemia was investigated along with the ESA requirement. The TC and FC values were very low in all patients before levocarnitine administration, and increased to a normal range 4 weeks after the administration and continued to increase over the following 12 weeks. The hemoglobin value increased by 1.0 g/dL or more in 7 of the 13 cases due to levocarnitine administration, while ESA was reduced by 25% or more in 4 cases, and was effective in a total of 9 cases (2 cases satisfying both standards). There were no significant differences between the effective example and ineffective example regarding the TC, FC, and acylcarnitine (AC) values as well as FC/AC ratio prior to levocarnitine administration. The TC and FC values 4 and 12 weeks after administration in the effective example were significantly higher than those in the ineffective example. The FC/AC ratio significantly increased in the effective example 4 and 8 weeks after administration compared with the prior value. Although red blood cell survival was shortened in 3 effective examples prior to administration, this improved following administration. Red blood cell survival in 2 ineffective examples did not improve, even after administration. As a result, levocarnitine substitution therapy appears to be highly effective in anemic hemodialysis patients without complicated diseases requiring high-quantity ESA, and its mechanism of action is mainly the improvement of shortened red blood cell survival.

In this clinical study, the reduction rate of FLCs by hemodiafiltration (HDF) using protein leaking dialyzer and hemodialysis using PMMA membrane were measured. The removal rates of κFLC were 20.8-71.6% by HDF and 54.7% by PMMA hemodialysis (HD). The removal rates of λFLC were 48.5-60.2% by HDF and 39.4% by PMMA HD. In an in vitro study, high cut-off membrane Theralite2100^<TM>, protein leaking dialyzer PES210Dα^<TM>, plasma separator Evacure1A20^<TM> and β2 microglobulin adsorption column LixelleS-35 were compared in their FLC removal rate. Dialysis using Theralite2100^<TM> or Evacure1A20^<TM>, diafiltration using PES210Dα^<TM> and adsorption using LixelleS-35^<TM> were performed in an in vitro circuit. The highest removal rate was obtained by Theralite2100 dialysis among the four blood purification methods. PES210Da^<TM> diafiltration has the second best removal rate. In conclusion, Theralite2100^<TM> dialysis was the best in removal of FLCs. In countries where Theralite2100^<TM> is not available, HDF using protein leaking dialyzer could become an alternative option.

通院中の血液透析患者でダルベポエチンα(DA)を週1回投与されている32例を対象とし、静注用鉄剤の投与方法別に、DAと同日に投与する群(9例)、DA投与の次の透析日に投与する群(11例)、DA投与の前の透析日に投与する群(12例)に無作為に分け、「赤血球造血」「鉄代謝」「酸化ストレス」に関わる諸指標の推移を群間比較した。結果、いずれの指標にも有意な群間差は認められなかった。このことから、DA週1回投与下にある透析患者において静注用鉄剤の投与日の違いは赤血球造血や酸化ストレスに影響を及ぼさず、どのタイミングで投与しても問題なく使用できると考えられた。